Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines

Gynecologic Oncology

Volumn 103, Issue 2, 2006, Pages 518-522

  Smith, Judith A ^a,b   Gaikwad, Anjali ^a   Ramondetta, Lois M ^a,b   Wolf, Judith K ^b   Brown, Jubilee ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cisplatin; Drug resistance; Endometrial cancer; Gemcitabine

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BAD; PROTEIN BAX; PROTEIN KINASE B; PROTEIN MSH2; PROTEIN P53;

ARTICLE; CANCER CELL; CANCER INHIBITION; DOWN REGULATION; DRUG MECHANISM; ENDOMETRIUM CANCER; ENZYME ACTIVATION; ENZYME ACTIVITY; EVALUATION; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CISPLATIN; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENDOMETRIAL NEOPLASMS; FEMALE; GLUTATHIONE; HUMANS;

EID: 33750159908     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.03.042     Document Type: Article

References (23)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Smith J.A., Brown J., Ramondetta L., and Wolf J.K. An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines. Gynecol Oncol 92 (2004) 314-319
3. Van Moorsel C.J.A., Veerman G., Vermorken J.B., Voorn D.A., Kroep J.R., Bergman A.M., et al. Mechanisms of synergism between gemcitabine and cisplatin. In: Griesmacher, et al. (Ed). Purine and pyrimidine metabolism in man IX (1998), Plenum Press, New York 581-585
4. Crul M., van Waardenburg R.C.A.M., Bocxe S., van Eijndhoven M.A.J., Plium D., Beijnen J.H., et al. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol 65 (2003) 275-282
5. Rose P.G., Mossbruger K., Fusco N., Smrekar M., Eaton S., and Rodriguez M. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 88 (2003) 17-21
6. Mujoo K., Watanabe M., Nakamura J., Khokar A.R., and Siddik Z.H. Status of p53 phosphorylatin and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents. J Cancer Res Clin Oncol 129 12 (2003) 709-718
7. Mujoo K., Zhang L., Klostergaard J., and Donato N.J. Emergence of cisplatin-resistant cells from the OVCAR-3 ovarian carcinoma cell line with p53 mutations, altered tumorigenicity, and increased apoptotic sensitivity to p53 gene replacement. Int J Gynecol Cancer (2000) 105-114
8. Samimi G., Fink D., Varki N.M., Husain A., Hoskins W.J., Alberts D.S., et al. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res 6 (2000) 1415-1421
9. Yang L.Y., Li L., Jiang H., Shen Y., and Plunkett W. Expression of ERCC1 antisense RNA abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 6 (2000) 773-781
10. Selvakumaran M., Pisarcik D.A., Bao R., Yeung A.T., and Hamilton T.C. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 63 (2003) 1311-1316
11. Ferry K.V., Hamilton T.C., and Johnson S.W. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells. Biochem Pharmacol 60 (2000) 1305-1313
12. Moufarij M.A., Phillips D.R., and Cullinane C. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines. Mol Pharmacol 63 4 (2003) 862-869
13. van Moorsel C.J.A., Pinedo H.M., Veerman G., Bergman A.M., Kuiper C.M., Vermorken J.B., et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non small cell lung cancer cell lines. Br J Cancer 80 7 (1999) 981-990
14. Crul M., van Waardenburg R.C.A.M., Bocxe S., van Eijndhoven M.A.J., Pluim D., Beijnen J.H., et al. DNA repair mechanism involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol 65 (2003) 275-282
15. Schuyer M., van der Burg M.E.L., Henzen-Logmans S.C., Fieret J.H., Klijn J.G.M., Look M.P., et al. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer 85 9 (2001) 1359-1367
16. Peters G.J., Bergman A.M., Ruiz van Haperen V.W., Veerman G., Kuiper C.M., and Braakhuis B.J. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22 4 suppl. 11 (1995) 72-79
17. Behrens B.C., Hamilton T.C., Masuda H., Grotzinger Kr., Whang-Peng J., Louie K.G., et al. Characterization of a cis-diamminedichloroplatinum (II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47 (1987) 414-418
18. Mistry P., Kelland L.R., Abel G., et al. The relationships between glutathione, glutathione S tranferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 64 (1991) 215-220
19. Lewis A.D., Hayes J.D., et al. Glutathione and glutathione dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance intrinsic differences and cell cycle effects. Carcinogenesis 9 (1988) 1283-1287
20. Hagopian G.S., Mills G.B., Khokhar A.R., Bast R.C., and Siddik Z.H. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Clin Cancer Res 5 (1999) 655-663
21. Fan S., Smith M.L., Rivet D.J., Duba D., Zhan Q., Kohn K.W., et al. Disruption of p53 sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55 (1995) 1649-1654
22. Hawkins D.S., Demers G.W., and Galloway D.A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56 (1996) 892-898
23. Villella J., Marchetti D., Odunsi K., Rodabaug K., Driscoll D.L., and Lele S. Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma. Gynecol Oncol 95 (2004) 539-545